Impax Reverse Payment About Dodging Competition, FTC Told
Federal Trade Commission staff attorneys urged the commission in oral arguments Thursday to revive a pay-for-delay case against Impax over the opioid pain medication Opana ER, arguing that brandmaker Endo Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article